All In Biotech

Drug Trial Radar · NCT04901676

Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia

A Phase 3, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Leronlimab in Combination With Standard of Care for Moderately Ill Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia

Last checked: Nov 19, 2026Latest source record: Apr 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingPhase 3. Randomized with 612 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

612

Planned (sponsor's estimate)

Start

Sep 9, 2021

Primary completion

Jan 2023

Study completion Feb 2023

Sponsor

Lead sponsor
Hospital Israelita Albert EinsteinAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
CytoDyn, Inc.
First posted
May 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Leronlimab (PRO 140) is a humanized IgG4,k monoclonal antibody (mAb) that recognizes the C-C chemokine receptor type 5 (CCR5). Disruption of the C-C chemokine ligand 5 (CCL5)-CCR5 axis via leronlimab-mediated CCR5 blockade might prevent pulmonary trafficking of pro-inflammatory leukocytes and dampen pathogenic immune activation in coronavirus disease 2019 (COVID-19). The purpose of the study is to assess the safety and efficacy of leronlimab plus standard of care in patients hospitalized with COVID-19 pneumonia who are not requiring mechanical ventilation or extracorporeal oxygenation (ECMO).

Conditions

  • COVID-19 Pneumonia

Interventions

  • LeronlimabDrug

    Leronlimab 700 mg (first dose) followed by weekly 350 mg

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative incidence of death or respiratory failure until day 28Time frame: 28 days

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Israelita Albert Einstein

    São Paulo, Brazil

  • Hospital Vitoria

    Vitória, Espírito Santo, Brazil

  • Clinica São Roque

    Ipiaú, Estado de Bahia, Brazil

  • Instituto de Ensino e Pesquisa do Hospital da Bahia

    Salvador, Estado de Bahia, Brazil

  • Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel

    Salvador, Estado de Bahia, Brazil

  • Hospital do Coração do Brasil

    Brasília, Federal District, Brazil

  • Hospital Felicio Rocho

    Belo Horizonte, Minas Gerais, Brazil

  • Santa Casa de Passos

    Passos, Minas Gerais, Brazil

  • Hospital São Lucas Copacabana

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Instituto Atena de Pesquisa Clínica

    Natal, Rio Grande do Norte, Brazil

  • Hospital São Vicente de Paulo

    Passo Fundo, Rio Grande do Sul, Brazil

  • Hospital Mãe de Deus

    Porto Alegre, Rio Grande do Sul, Brazil

  • Irmandade da Santa Casa de Misericórdia Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Fundação PIO XII

    Barretos, São Paulo, Brazil

  • Irmandade do Sr. Bom Jesus dos Passos da Santa Casa de Misericórdia de Bragança Paulista

    Bragança Paulista, São Paulo, Brazil

  • Instituto de Pesquisa Clínica de Campinas

    Campinas, São Paulo, Brazil

  • Santa Casa de Santos

    Santos, São Paulo, Brazil

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto

    São José do Rio Preto, São Paulo, Brazil

  • Associação Beneficente Síria - Hospital do Coração (HCor)

    São Paulo, São Paulo, Brazil

  • BP Mirante

    São Paulo, São Paulo, Brazil

  • Hospital 9 de Julho

    São Paulo, São Paulo, Brazil

  • Hospital Alemão Oswaldo Cruz

    São Paulo, São Paulo, Brazil

  • Hospital Beneficência Portuguesa

    São Paulo, São Paulo, Brazil

  • Hospital M'Boi Mirim

    São Paulo, São Paulo, Brazil

  • Hospital Santa Paula

    São Paulo, São Paulo, Brazil

  • Santa Casa de Votuporanga

    Votuporanga, São Paulo, Brazil

  • Centro de Pesquisa Clínica do Coração

    Aracaju, Sergipe, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.